hydroxychloroquine - for COVID-19 method

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA
clinical improvement 1.91 [0.80, 4.53]> 148%2 studies (2 / -)92.8 %highnot evaluable lowcrucial-
clinical improvement (14-day) 1.37 [0.73, 2.56]> 10%1 study (1 / -)83.8 %some concernnot evaluable moderatecrucial-
clinical worsening 1.01 [0.81, 1.25]< 10%4 studies (1 / 3)47.7 %seriousnot evaluable lowcrucial-
deaths 0.75 [0.50, 1.13]< 191%9 studies (1 / 8)91.5 %criticalnot evaluable very lowcrucial-
deaths (time to event analysis only) 0.84 [0.56, 1.28]< 193%7 studies (1 / 6)78.6 %criticalnot evaluable very lowcrucial-
death or ventilation 1.04 [0.82, 1.32]< 10%1 study (- / 1)37.3 %seriousnot evaluable lowimportant-
PCR-negative conversion 3.10 [0.10, 100.72]> 181%2 studies (1 / 1)73.5 %seriousnot evaluable lowimportant-
PCR-negative conversion (14-day) 1.09 [0.95, 1.26]> 10%1 study (1 / -)88.2 %some concernnot evaluable moderateimportant-
PCR-negative conversion (7-day) 1.12 [0.58, 2.19]> 10%2 studies (2 / -)63.2 %some concernnot evaluable moderateimportant-
radiologic improvement (14-day) 1.33 [0.94, 1.88]> 10%1 study (1 / -)94.7 %some concernnot evaluable moderateimportant-
radiologic improvement (7-day) 3.43 [1.10, 10.70]> 10%1 study (1 / -)98.3 %highnot evaluable lowimportant-
radiologic progression 0.57 [0.13, 2.50]< 10%1 study (1 / -)77.1 %some concernnot evaluable moderateimportant-
ventilation (time to event analysis only) 1.43 [0.53, 3.82]< 10%1 study (- / 1)23.8 %seriousnot evaluable lowimportant-
adverse events 1.80 [0.14, 23.37]< 10%1 study (1 / -)32.8 %some concernnot evaluable moderatenon important-
cardiac arrest 1.91 [0.96, 3.81]< 10%1 study (- / 1)3.3 %seriousnot evaluable lowimportant-
abnormal ECG findings 1.50 [0.88, 2.57]< 10%1 study (- / 1)7.0 %seriousnot evaluable lownon important-
arrhythmia 1.67 [0.97, 2.86]< 10%1 study (- / 1)3.1 %seriousnot evaluable lownon important-
diarrhea and abnormal liver function 1.45 [0.26, 8.01]< 10%1 study (1 / -)33.4 %some concernnot evaluable moderatenon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 4 pathologies: 87,95,94,90,91,97 95, 90, 91, 87